Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

Stewart, A. Keith; Rajkumar, S. Vincent; Dimopoulos, Meletios Α.; Masszi, Tamás; Špıčka, Ivan; Oriol, Albert; Hájek, Roman; Rosiñol, Laura; Siegel, David S.; Mihaylov, Georgi; Goranova‐Marinova, Vesselina; Rajnics, Péter; Suvorov, Aleksandr; Niesvizky, Rubén; Jakubowiak, Andrzej; Miguel, Jesús F. San; Ludwig, Heinz; Wang, Michael; Maisnar, Vladimír; Minařík, Jiří; Bensinger, William; Mateos, María-Victoria; Ben‐Yehuda, Dina; Kukreti, Vishal; Zojwalla, Naseem J.; Tonda, Margaret; Yang, Xinqun; Xing, Biao; Moreau, Philippe; Palumbo, Antonio

doi:10.1056/nejmoa1411321

articleNew England Journal of MedicineDec 6, 2014BRONZE OA

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

AKA. Keith Stewart SVS. Vincent Rajkumar MΑMeletios Α. Dimopoulos TMTamás Masszi IŠIvan Špıčka

Apple (Israel) · Mayo Clinic in Arizona · +29 more institutions

PubMed

Indexed incrossrefpubmed

Abstract

Background

Lenalidomide plus dexamethasone is a reference treatment for relapsed multiple myeloma. The combination of the proteasome inhibitor carfilzomib with lenalidomide and dexamethasone has shown efficacy in a phase 1 and 2 study in relapsed multiple myeloma.

Methods

We randomly assigned 792 patients with relapsed multiple myeloma to carfilzomib with lenalidomide and dexamethasone (carfilzomib group) or lenalidomide and dexamethasone alone (control group). The primary end point was progression-free survival.

Citation impact

1,320

total citations

FWCI: 76.28
Percentile: 100%
References: 34

Citations per year

Authors

30

Topics & keywords

Topics

Keywords

Carfilzomib
Lenalidomide
Medicine
Dexamethasone
Multiple myeloma
Oncology
Proteasome inhibitor
Internal medicine

UN Sustainable Development Goals

Good health and well-being

No related works found for this paper.